Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar) from NMPA (CFDA) to Treat NSCLC

 Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar) from NMPA (CFDA) to Treat NSCLC

Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China

Shots:

  • The BLA is based on two P-III study results assessing efficacy, safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity
  • Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab, biosimilar) in H2’18 for ankylosing spondylitis (AS), rheumatoid arthritis (RA) & psoriasis and r/r classical Hodgkin’s lymphoma respectively
  • Avastin’s biosimilar IBI-305 (bevacizumab) is an anti-VEGF mAb, involved in inhibiting PI3K-Akt/PKB & Ras-Raf-MEK-ERK pathways and targeted for NSCLC, colorectal cancer and other malignant tumors

 Click here to read full press release/ article | Ref: PRNewswire | Image: China Knowledge

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post